Daewoong Pharmaceutical Co., Ltd.
KKRX:069620102,400.00
KRW
-500.00
(-0.49%)
ISIN
KR7069620003
Return %
Stock
S&P 500
1Y
-24.65
14.39
3Y
1.99
81.42
5Y
-27.38
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Chang-Jae Lee
- Full Time Employees
- 1,794
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 12, Bongeunsa-ro 114-gil Hwaseong-si GY South Korea 135-715
- IPO Date
- Nov 1, 2002
- Website
- daewoong.co.kr
- Similar Companies
- Business
- Daewoong Pharmaceutical Co., Ltd. is a South Korean pharmaceutical company that develops, manufactures, and commercializes pharmaceutical products domestically and internationally. Founded in 1945 and headquartered in Seoul, the company offers a broad range of pharmaceuticals including prescription drugs and over-the-counter products across therapeutic areas such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, digestive diseases, wound care, iron supplements, and multivitamins. Key product lines include biologics and chemical finished dosage formulations, active pharmaceutical ingredients, antibiotics, enzymes, and medical devices with notable products like Envlo (enavogliflozin) for type 2 diabetes, Fexuclue (fexuprazan) for acid-related diseases, Luphere Depot for prostate cancer and other hormone-related conditions, and Olostar, a fixed-dose combination for hypertension and dyslipidemia. The company is active in both the domestic Korean market and international markets including the Philippines, Chile, Ecuador, and the United States. In recent years, Daewoong Pharmaceutical has focused on innovation through partnerships and new drug development. In 2025, it entered a strategic research collaboration with Swedish biotech Salipro Biotech to leverage Salipro’s platform for stabilizing challenging membrane proteins to advance its small molecule drug discovery pipeline. The company also expanded its R&D with the development of a new antidiabetic medication showing successful phase 3 trial results, and obtained clearance from the U.S. FDA for a first-in-class oral dual acting inhibitor for autoimmune diseases, demonstrating a move toward novel drug classes and increased presence in the U.S. market. Additionally, Daewoong regained rights to its drug fexuprazan in the U.S. and Canada following the termination of a previous license agreement, signaling a strategic pivot in regional operations. It continues to invest in expanding its biologics and chemical product portfolio while maintaining strong sales in the Korean domestic market, where it holds the largest prescription drug sales. The company also recently partnered with Sonoma Pharmaceuticals to enhance distribution of wound care products in South Korea, further diversifying its product and market reach. Overall, Daewoong Pharmaceutical pursues growth through innovation, strategic alliances, and broadened geographic focus while maintaining a comprehensive pharmaceutical product offering rooted in advanced platform technologies.